HUM.US Weekly Report · 2026-W31
Overview
Humana experienced significant volatility this week, with intraweek amplitude reaching 9.3% and Friday’s close at $363.86, down 0.76% from last Friday. The core pressure stems from Q2 earnings “growth disconnect”—while revenue grew 26.2% to $40.87 billion and EPS grew 27.05% YoY to $5.73, the company’s full-year 2026 profit guidance cut overshadowed gains, reflecting Medicare Advantage cost pressures that diverge from market expectations. Institutional flows remain positive, but rating divergence is widening, and uncertainty over execution capability persists.
Market Price Action
This week (July 27–31, 2026) closed at $363.86, declining 8.29% from last week’s final trading session (July 24, close: $396.75). Intraweek amplitude of 9.3% (high $372.15 vs. low $362.86) significantly exceeds the 60-day average daily volatility, reflecting elevated market sentiment swings.
Volume this week totaled 14.548 million shares with $5.328 billion in turnover. Relative to the 60-day chart, Friday’s 1.454 million share volume came in below the recent high (July 29: 4.11 million shares), but week-to-date turnover showed no broad compression. Mid-week sessions (July 27–28) exhibited heavy volume as the decline initiated (2.25–2.25 million shares), indicating full engagement during the selloff. The pattern shows substantial liquidity throughout, though directionality remained unclear.
Key candlestick pattern: Monday (July 27) opened the sell-off with a 1.82% decline; Tuesday (July 28) bounced +2.08% intraday; Wednesday (July 29) plunged 6.39% to the week’s low; Thursday (July 30) recovered slightly (+0.34%); Friday closed down 0.76%. The overall sequence reflects “rally-reversal-plunge-weak bounce-selloff,” consistent with multiple-test lows with full order flow engagement.
Valuation and Earnings
As of July 30 (latest snapshot), HUM.US trades at a P/E multiple of 34.42x, placing it at approximately the 10.65th percentile over the past 3 years—a relatively low valuation band. Against the healthcare peer median of 27.10x, current valuation sits modestly above industry average.
Q2 2026 reported EPS of $5.73, up 27.05% YoY; sequentially down 41.8% from Q1 2026 ($9.83). Operating revenue reached $40.87 billion, up 26.18% YoY and 3.08% QoQ. Net income: $693 million, up 27.34% YoY, down 41.5% QoQ. ROE: 14.69%, declining 43.8% QoQ.
Against consensus estimates (July 31 snapshot), full-year 2026 consensus EPS stands at $12.32, with a median of $12.48. Q2 actual EPS of $5.73 vs. IBES estimate of $7.22 came in 20.7% below consensus, the primary trigger for the stock’s correction. The company simultaneously lowered full-year EPS guidance, signaling material earnings pressure in H2.
Capital Flows
Capital inflows persisted this week. Per Longbridge data (as of July 31, 20:00 UTC), large trades net inflow of $270.31 million, mid-size trades net inflow of $250.81 million, and retail (small trades) net outflow of $261.47 million. The pattern reflects institutional accumulation amid retail capitulation.
Timing coincides with earnings release (July 29, Tuesday), when flows diverged sharply: retail dumped heaviest on Tuesday’s plunge (net outflow $139.05 million), while institutions absorbed selectively. This reveals institutional “bottom fishing” amid panic selling, while retail investors shifted to risk-off.
Institutional Ratings
As of July 31, institutional coverage stands at 26 analysts: 11 strong buys, 1 buy, 12 holds, 2 sells. Coverage exceeds the healthcare peer median (19 analysts), indicating above-average attention. HUM ranks 2nd among 9 managed healthcare stocks in the sector.
Price targets span from a low of $249 to a high of $513, with the current price of $366.66 in the upper half of the band. The consensus recommendation is “buy” with an average target of $407.83, implying 11.2% upside. However, multiple analysts have shifted post-earnings—some from bullish to neutral—underscoring the lagged nature of rating signals.
Weekly News Summary
The dominant event this week was Q2 earnings release and full-year guidance cut. While quarterly revenue (+26%) and profit growth met expectations, two factors sparked repricing: first, EPS of $5.73 missed consensus of $7.22 by 20.7%; second, management lowered 2026 profit guidance citing rising medical costs in Medicare Advantage plans, guiding Q3 insured benefit ratios slightly above 94%. Markets read this as “growth masking profitability stress,” triggering shifts from strong bullish to cautious stances.
Alongside earnings, Humana announced an Anthropic executive joining the board, signaling interest in healthcare AI/analytics applications—a bright spot that faded under earnings-guidance gloom.
Several analysts adjusted post-earnings: Bank of America upgraded to buy pre-report, but peers turned cautious to neutral thereafter. Skeptical analysts cite Medicare Advantage plan headwinds as likely to persist through year-end, exceeding prior-market assumptions.
Related news (ordered by date and importance):
- Humana slides 8% as Medicare pressure drives 2026 EPS cut
- Humana Inc Q2 2026: Revenue $40.9B, EPS $5.73— 10-Q Summary
- Humana FY26 Q2 net income rises 27.6% to $693 million; revenue climbs 26.2% to $40.87 billion
- Humana Q2 Profit Climbs, Cuts FY26 EPS Outlook, Backs Adj. Earnings, Revenue View; Stock Down
- Humana’s Strong Quarter Fails To Impress
- Humana (NYSE:HUM) Upgraded to Buy at Bank of America
- Humana adds Anthropic executive Paul Smith to board
- US Insurer Humana Is Exiting More Medicare Advantage Plans in 2027— Here’s Who Could Be Affected
- This Humana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
- Humana Price Target Raised to $370 as Margin Recovery Prospects Balance Ongoing Execution Risks, Supporting Hold Rating
Contradictions and Coherence
The week’s core contradiction lies in fundamental backdrop vs. market repricing: low valuation (P/E at ~10.65th percentile) + bullish institutional ratings + positive capital flows—all three traditionally bullish signals align in one direction. Yet the stock fell 8.29%, revealing that earnings quality concerns have overtaken valuation cheapness and rating optimism.
The contradiction’s root is information lag: the 26-analyst consensus issued mostly pre-earnings; while some adjusted post-release, the collective rating system struggles to quickly absorb 20%+ EPS misses. Capital flows show institutional bottom-fishing (main buyer), but concentrated retail liquidation (Tuesday net outflow $139 million) signals sharply lower risk appetite among retail players.
A second layer of contradiction emerges from profit vs. cash flow divergence: YoY revenue and net income both grew 26%+, appearing healthy, yet ROE contracted 43.8% QoQ, and Q2 EPS trailed year-to-date average significantly. This implies H2 earnings guidance was materially cut, meaning much of Q2 “growth” came from pricing rather than cost discipline—and rising medical cost headwinds will likely persist Q3–Q4.
Synthesis: near-term pressure stems from earnings certainty erosion, not growth deceleration. Low valuation offers no safety buffer if profitability guidance keeps rolling downward. Risk hinges on Q3 medical cost control and the precise revenue drag from MA plan exits. Investors should focus on September pre-Q3-earnings guidance revisions rather than assuming current valuations are inherently attractive.